Swiss Group for Clinical Cancer Research
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Private
- Established
- 1965-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.sakk.ch/
Drugs to Reduce the Side Effects of Chemotherapy
- Conditions
- Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 267
- Registration Number
- NCT00003213
- Locations
- ๐ฎ๐น
Istituto Europeo Di Oncologia, Milano, Italy
๐จ๐ญKantonspital Aarau, Aarau, Switzerland
๐จ๐ญOffice of Walter Weber-Stadelman, Basel, Switzerland
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 300
- Registration Number
- NCT00003214
- Locations
- ๐จ๐ญ
Kantonspital Aarau, Aarau, Switzerland
๐จ๐ญFrauenspital, Basel, Basel, Switzerland
๐จ๐ญOffice of Walter Weber-Stadelman, Basel, Switzerland
Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 33
- Registration Number
- NCT00003230
- Locations
- ๐จ๐ญ
Kantonspital Aarau, Aarau, Switzerland
๐จ๐ญOffice of Walter Weber-Stadelman, Basel, Switzerland
๐จ๐ญUniversity Hospital, Basel, Switzerland
Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 224
- Registration Number
- NCT00002654
- Locations
- ๐จ๐ญ
Universitaetsspital, Zurich, Switzerland
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 40
- Registration Number
- NCT00003231
- Locations
- ๐จ๐ญ
Kantonspital Aarau, Aarau, Switzerland
๐จ๐ญOffice of Walter Weber-Stadelman, Basel, Switzerland
๐จ๐ญUniversity Hospital, Basel, Switzerland
Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- Prostate Cancer
- First Posted Date
- 2004-03-24
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Registration Number
- NCT00006023
- Locations
- ๐จ๐ญ
Spitalzentrum Biel, Biel, Switzerland
๐จ๐ญKantonsspital - Saint Gallen, Saint Gallen, Switzerland
Biological Therapy in Treating Patients With Bladder Cancer
- Conditions
- Bladder Cancer
- First Posted Date
- 2004-03-15
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 40
- Registration Number
- NCT00003779
- Locations
- ๐จ๐ญ
Inselspital, Bern, Bern, Switzerland
Chemotherapy in Treating Patients With Advanced Sarcoma
- Conditions
- Ovarian CancerSarcoma
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT00002526
- Locations
- ๐จ๐ญ
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Extrahepatic Bile Duct CancerGallbladder CancerLiver CancerPain
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 44
- Registration Number
- NCT00073905
- Locations
- ๐จ๐ญ
Kantonsspital - St. Gallen, St. Gallen, Switzerland
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
- Conditions
- Leukemia
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 43
- Registration Number
- NCT00072007
- Locations
- ๐จ๐ญ
Kantonspital Aarau, Aarau, Switzerland
๐จ๐ญOncology Institute of Southern Switzerland, Bellinzona, Switzerland
๐จ๐ญInselspital Bern, Bern, Switzerland